Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

Steve Lu, Julie E. Stein, David L. Rimm, +11

JAMA Oncology

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Tricia R. Cottrell, Elizabeth D. Thompson, Patrick M. Forde, +27

Annals of Oncology

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

Suzanne L. Topalian, Shailender Bhatia, Asim Amin, +21

Journal of Clinical Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M.T. Tetzlaff, Jane L. Messina, Julie E. Stein, +20

Annals of Oncology

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Robert L. Ferris, William C. Spanos, Rom S. Leidner, +16

Journal for ImmunoTherapy of Cancer

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Sneha Berry, Nicolás A. Giraldo, Benjamin Green, +34

Science

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

Nicolás A. Giraldo, Peter Nguyen, Elizabeth L. Engle, +24

Journal for ImmunoTherapy of Cancer

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Julie E. Stein, Evan J. Lipson, Tricia R. Cottrell, +12

Clinical Cancer Research

Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis

Sven D. Sommerfeld, Christopher Cherry, Liam Chung, +10

Science Immunology

Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer

Wolfgang Kern, B. Beckert, Nicola Lang, +7

Annals of Oncology

OncologyHepatologyMedicineFolinic AcidColorectal Cancer +6